A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral lenalidomide to standard induction therapy in AML and RAEB ≥ 66 years and very poor risk AML ≥ 18 years.

Cancer type: Leukemia

Phase: II

Principal Investigator: Gjertsen Bjørn Tore

Country: NO

Keywords: Norway, Bergen

Status: Inclusion completed